Literature DB >> 15837546

Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer.

Zhi-Jie Cheng1, Kaleeckal G Harikumar, Wei-Qun Ding, Eileen L Holicky, Laurence J Miller.   

Abstract

Gastrin and cholecystokinin (CCK) have trophic action on cells expressing wild type A or B CCK receptors. Potential relevance to pancreatic and colonic cancers was raised by the demonstration of a misspliced type B CCK receptor that, when expressed in Balb3T3 cells, had constitutive activity to stimulate intracellular calcium. We attempted to confirm and extend this observation in CHO cells by establishing lines expressing similar densities of variant or wild type B CCK receptor. While both were capable of normal binding and agonist-induced signaling, neither expressed constitutive signaling and both had similar basal growth. Agonist stimulation of cells expressing misspliced receptor had greater increases in calcium and greater growth rates than control cells despite similar MAP kinase phosphorylation responses. Thus, this variant receptor can potentiate peptide-stimulated signaling and trophic action and may contribute to the proliferation of neoplasms expressing it.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837546     DOI: 10.1016/j.canlet.2004.09.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.

Authors:  Kaleeckal G Harikumar; Eyup Akgün; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

2.  Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway.

Authors:  Jin Zhou; Zi-Xiang Zhang; De-Chun Li
Journal:  Curr Ther Res Clin Exp       Date:  2010-08

3.  A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.

Authors:  Jill P Smith; John F Harms; Gail L Matters; Christopher O McGovern; Francesca M Ruggiero; Jiangang Liao; Kristin K Fino; Emily E Ortega; Evan L Gilius; John A Phillips
Journal:  Cancer Biol Ther       Date:  2012-02-01       Impact factor: 4.742

4.  Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.

Authors:  Kaleeckal G Harikumar; Maoqing Dong; Zhijie Cheng; Delia I Pinon; Terry P Lybrand; Laurence J Miller
Journal:  Biochemistry       Date:  2006-12-12       Impact factor: 3.162

5.  CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells.

Authors:  Celia Chao; Xueliang Han; Kirk Ives; Jeseong Park; Andrey A Kolokoltsov; Robert A Davey; Mary P Moyer; Mark R Hellmich
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

Review 6.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

7.  Permanent Photodynamic Activation of the Cholecystokinin 2 Receptor.

Authors:  Wen Zhu Tang; Zong Jie Cui
Journal:  Biomolecules       Date:  2020-02-04

8.  CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours.

Authors:  Meike Körner; Beatrice Waser; Jean Claude Reubi; Laurence J Miller
Journal:  J Cell Mol Med       Date:  2009-07-20       Impact factor: 5.310

9.  Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymph Nodes of NOD mice is associated with Islet Autoimmunity.

Authors:  Béatrice Regnault; José Osorio Y Fortea; Dongmei Miao; George Eisenbarth; Evie Melanitou
Journal:  BMC Med Genomics       Date:  2009-10-02       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.